Document hub

Our international presence

Return to Hikma.com
Contact Us

Popular searches

What we do

We bring patients across North America, MENA and Europe a broad range of generic, specialty and branded pharmaceutical products.

We have three distinct businesses that enable us to create high-quality medicines and make them accessible to those who need them.

We have 29 manufacturing plants, 3 R&D hubs and c.9,500 employees worldwide, manufacturing and supplying over 800+ products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

Learn more about what we do

Injectables

We are the third largest supplier of generic injectables in the US [1]. We supply hospitals across our markets with generic injectable products, supported by our manufacturing facilities in the US, Europe and MENA.

Branded

We are the largest pharmaceutical company in MENA1. We supply branded generics and in-licensed patented products from our local manufacturing facilities to retail and hospital customers across the MENA region.

generics Branded generics MENA

Hikma Rx

We supply oral and other non-injectable generic and specialty branded products to the US retail market, leveraging our state-of-art manufacturing facility in Columbus, Ohio.
Core revenue 2025
$ 1,423 m Injectables
$ 849 m Branded
$ 1,037 m Hikma Rx

1. Based on internal analysis using data from the following source: IQVIA MIDAS® Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and UAE, for the period: MAT December 2025, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved
2. IQVIA MAT November 2025, generic injectable volumes by eaches, excluding branded generics and Becton Dickinson
3. IQVIA Injectable generic products, Hospital + Germany Retail, 2024 USD sales

Discover more

Operations
Partnering with Hikma
Contract manufacturing